Refine by
Amoydx Clinically Studied Equipment & Supplies
2 equipment items found
Manufactured by:Amoy Diagnostics Co., Ltd. based inXiamen, CHINA
25%, for BRAF1-4%, for NRAS is 1%, for HER2 2-4%, and for PIK3CA 1-3%. About 3-7% of NSCLC patients have gene fusion in ALK, 2% in ROS1, and 1% in RET. A large amount of clinical studies showed that gene mutation status is important efficacy predictor for targeted therapy. ...
Manufactured by:Amoy Diagnostics Co., Ltd. based inXiamen, CHINA
PIK3CA mutations in which lead to Activation of the PI3K pathway in breast cancer have been typically associated with resistance to endocrine therapy and poor prognosis. The clinical studies demonstrate that PI3K inhibitors has shown significantly high response rate in patients with PIK3CA-mutated breast ...